Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled trial of TG103 injection for non-diabetic overweight or obesity
CTR20251416Phase 3Completed
- Sponsor
- CSPC Baike Biopharmaceutical
- Start
- Apr 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of GX-G6 in obesity, Overweight, sponsored by CSPC Baike Biopharmaceutical. Started Apr 2025; status: completed.
02
Drugs
GX-G6
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20251416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251416.